Our Pipeline

Classification / Fields

Lead Optimization

cGMP

Tox / IND

Phase 1

Phase 2

Phase 3

ImmSygma Vaccine Adjuvants

IA-05

Saponin Adjuvant

IA-41

TLR4 Agonist

IAS-01

Adjuvant System

Vaccine Candidate

IA-C01

Vaccine

Others (undisclosed)

IA-C03

Immune Modulation

IA-38

SMDC

ImmunAdd develops innovative and practical solutions for human health. We aim to harness the immune system to create next-generation immunotherapeutics for the treatment of infectious diseases and cancer. Our next-generation adjuvants provide better immune activities in combination with anti-infection and anti-cancer vaccines. ImmunAdd has developed an efficient and sustainable manufacturing process for IA-05. With POC purpose, ImmunAdd will continue to expand our development to clinical-stage programs.